RxDoctor Payments Data

Fernando Scaglia

Clinical Genetics (M.D.) · Houston, TXNPI 1518047943

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $13,470 of the $15,849 with a category attached, or 85.0%. UCB, Inc. accounts for 61.6% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2024 at $9,578 and has fallen 82.3% since, to $1,693 in 2025.

$15,849in general payments, 2019–2025

Across 23 payments — averaging $689.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$10K
  • UCB SA$6K
  • Amicus Therapeutics, Inc.$31
  • Biomarin Pharmaceutical Inc.$23
$1,059,610in research payments, 2019–2025

Across 104 payments — averaging $10,189 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • PTC Therapeutics, Inc.$878K
  • Astellas Pharma Inc$158K
  • UCB Biosciences Inc.$16K
  • UCB SA$7K

What the payments were for

  • Consulting fees$13,47085%
  • Travel & lodging$1,76211%
  • Food & beverage$6174%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$15,849 in reported general payments places this provider in the 75th percentile of 37 clinical genetics (m.d.) providers in Texas.

See all clinical genetics (m.d.) providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
Miglustat22$257,814
Leucovorin Calcium11$756

Paid to pharmacies, not to this prescriber.

Other clinical genetics (m.d.) in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →